Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis
Olatoyosi Odenike(University of Chicago), Wendy Stock(University of Chicago), Rebecca B. Klisovic(Goethe University Frankfurt), Koen van Besien(University Hospitals of Cleveland), James L. Wade(American Society of Clinical Oncology), Maria R. Baer(University of Maryland, Baltimore), John E. Godwin(Providence Portland Medical Center), Julia Melnick(University of Chicago Medical Center), Scott E. Smith(Loyola University Medical Center), Dorie Sher(University of Chicago Medical Center), Margaret Green, Patrick W. Burke, Eric P. Lester, Dezheng Huo(University of Chicago Medical Center)
Cited by 32
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k